Brief: Cyxone Assigns Aptuit For The Capsulation Of Phase II Candidate Rabeximod

Cyxone AB

02/12/2019 11:07

Dec 2 (Reuters) - Cyxone AB  CYXO.ST :
    * CYXONE ASSIGNS APTUIT FOR THE CAPSULATION OF PHASE II
CANDIDATE
RABEXIMOD
    * HAS SIGNED AN AGREEMENT WITH APTUIT, AN EVOTEC COMPANY, TO
PERFORM CAPSULATION OF RABEXIMOD SUBSTANCE
    * WORK WITH APTUIT IS PLANNED TO BE INITIATED EARLY NEXT
YEAR
    * AIM OF PHASE IIB STUDY IS TO CONFIRM RABEXIMOD'S
THERAPEUTIC
EFFECT AS WELL AS GOOD SAFETY AND TOLERABILITY.

Source text for Eikon:  ID:nWkr45Q8VQ 
Further company coverage:  CYXO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))